🇺🇸 FDA
Patent

US 10889587

Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use

granted A61KA61K45/06A61P

Quick answer

US patent 10889587 (Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use) held by SPERO THERAPEUTICS, INC. expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SPERO THERAPEUTICS, INC.
Grant date
Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K45/06, A61P, A61P31/04